Cps Technologies Corp

This non-binding proposal asks stockholders to approve the Company’s disclosed compensation for its named executive officers. Management frames the proposal as a check on alignment between pay and company performance and emphasizes that compensation in 2025 reflected improved financial results (revenues increased ~54% to $32.6 million and net income of $0.4 million) and specific performance milestones; bonuses and salary increases were granted in 2025 and equity awards were issued. The Board supports the proposal, stating that the programs create an ownership culture, align incentives with long-term stockholder value, and help attract and retain executives. The vote is advisory and will not override the Board or Compensation Committee but will be reviewed and considered in future compensation determinations. For investors evaluating the proposal, notable context includes the Company’s recent return to profitability in 2025, discretionary bonus accruals for named executives totaling approximately $211,000 for 2025, and recent option grants to executives and directors in February 2025. The Company’s governance disclosures indicate the Compensation Committee is independent and tied to the Board, and compensation decisions consider company performance, peer benchmarks and individual contributions; however, the advisory nature of the vote limits its enforceability. A “For” vote signals support for the Board’s compensation philosophy; a negative vote could trigger further engagement and potential program adjustments by the Board. Risk considerations include potential misalignment of incentive structures, dilution from equity awards, and limited shareholder remedies because the vote is non-binding.

This non-binding proposal asks shareholders to select the frequency (1, 2, or 3 years) of future advisory votes on executive compensation. The Board recommends an annual (1-year) frequency, arguing that annual votes make compensation more responsive to shareholder feedback and limit the potential for poor compensation choices to persist. In evaluating the recommendation, note that the Company previously received an annual vote in 2020 and that annual votes are common for smaller companies seeking frequent shareholder engagement. A plurality outcome will guide the Board but will not bind it; the Compensation Committee will consider the stockholder preference when setting policy. The choice affects how often investors can formally register approval or concern about pay practices; more frequent votes increase accountability but can raise administrative costs and potential short-termism, while less frequent votes can reduce engagement. For sophisticated investors, the relevant context includes the Company’s recent pay decisions tied to 2025 performance, the Compensation Committee’s independence, and the non-binding nature of the outcome. Given the Board’s explicit recommendation and the Company’s stated desire for responsive governance, a vote for a one-year frequency would align with management’s stated governance approach. Broader market practice and investor preferences should also be considered when assessing whether the board’s recommendation adequately balances accountability and long-term focus.

The proposal requests shareholder approval to amend the Company’s Restated Certificate of Incorporation to increase authorized common stock from 20 million to 25 million shares. Management states the rationale is to provide flexibility to issue shares for the 2020 Stock Incentive Plan, equity financings, or acquisitions, and notes there is no current plan to issue the additional shares. The filing discloses that as of March 11, 2026, approximately 18.0 million shares were issued and outstanding, ~1.46 million reserved for issuance under options and ~0.53 million unreserved, highlighting limited remaining headroom under the current authorization. The Board acknowledges potential dilutive effects, adverse impacts on EPS and book value per share, and potential anti-takeover implications, while asserting that the proposal is not presented as an anti-takeover device. For an analyst, material considerations include the company’s recent option grants (including 190,000 options granted Feb 28, 2025), outstanding equity plan capacity, the lack of preemptive rights for existing shareholders, and the Board’s ability to issue authorized shares without additional shareholder approval except as required by law or listing rules. Approval would permit the Board to act quickly to pursue financing or strategic transactions but also raises governance considerations around shareholder dilution and potential use of shares to entrench management. The Board’s recommendation and disclosure of effects and possible anti-takeover consequences provide transparency, but investors should weigh the probability and purpose of future issuances against dilution risk and the company’s capital needs and strategic plans.